Literature DB >> 6705136

Repeated daunomycin administration in rats. Pharmacokinetics and bone marrow toxicity.

K Nooter, P Sonneveld, J Deurloo, R Oostrum, F Schultz, A Martens, A Hagenbeek.   

Abstract

In the experiments described here, rats received three IV bolus injections (7.5 mg/kg) of daunomycin. The plasma data obtained after a single IV injection could be described by a two-compartment open model with t1/2 alpha and t1/2 beta values of 18.4 and 472.1 min. Of the tissues, the lungs contained the most daunomycin per gram of tissue, followed by the kidneys, liver, heart, and spleen. Daunomycinol was the main metabolic product and no substantial differences were found in daunomycinol content among the different organs. For all tissues and plasma, higher drug concentration values than would be expected on the basis of accumulation alone were observed after the second but not after the third injection. The cumulative urine excretion of daunomycin and daunomycinol remained essentially unchanged after one, two, and three daunomycin injections. However, the cumulative bile excretion increased after repeated daunomycin administration. The experiments in which the myelotoxicity was assessed by CFU-S survival after daunomycin treatment showed that three successive daunomycin administrations lead to a proportional reduction in stem cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6705136     DOI: 10.1007/bf00256543

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  5 in total

1.  Adriamycin-a review.

Authors:  S K Carter
Journal:  J Natl Cancer Inst       Date:  1975-12       Impact factor: 13.506

Review 2.  Adriamycin. A new anticancer drug with significant clinical activity.

Authors:  R H Blum; S K Carter
Journal:  Ann Intern Med       Date:  1974-02       Impact factor: 25.391

3.  The proliferative state of normal hemopoietic stem cells during progression of leukemia. Studies in the BN acute myelocytic leukemia (BNML).

Authors:  A Hagenbeek; A C Martens
Journal:  Leuk Res       Date:  1981       Impact factor: 3.156

4.  Determination of daunorubicin, doxorubicin and their fluorescent metabolites by high-pressure liquid chromatography: plasma levels in DBA2 mice.

Authors:  R Baurain; D Deprez-De Campeneere; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

5.  Dose response evaluation of adriamycin in human neoplasia.

Authors:  R M O'Bryan; L H Baker; J E Gottlieb; S E Rivkin; S P Balcerzak; G N Grumet; S E Salmon; T E Moon; B Hoogstraten
Journal:  Cancer       Date:  1977-05       Impact factor: 6.860

  5 in total
  2 in total

Review 1.  A Critical Review of Animal Models Used in Acute Myeloid Leukemia Pathophysiology.

Authors:  Hala Skayneh; Batoul Jishi; Rita Hleihel; Maguy Hamieh; Nadine Darwiche; Ali Bazarbachi; Marwan El Sabban; Hiba El Hajj
Journal:  Genes (Basel)       Date:  2019-08-13       Impact factor: 4.096

2.  Tumour response to chemotherapy in animals that have been treated with the same drugs prior to tumour implantation: a model for studying host effects on apparent drug resistance.

Authors:  C K Luk; I F Tannock
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.